Obligation Allergant Capital SARL 2.625% ( XS1909193317 ) en EUR

Allergant Capital SARL

95.17 % ▼

Etats-unis

XS1909193317 ( en EUR )

2.625% par an ( paiement annuel )

14/11/2028

Prospectus brochure de l'obligation Allergan Capital SARL XS1909193317 en EUR 2.625%, échéance 14/11/2028

/

/

15/11/2025 ( Dans 58 jours )

Allergan Capital SARL est une société de capital-investissement spécialisée dans les investissements dans le secteur de la santé, notamment dans les domaines pharmaceutique, biotechnologique et des dispositifs médicaux.

Une obligation d'entreprise, identifiée par le code ISIN XS1909193317, est actuellement observée sur le marché financier, émise par Allergan Capital SARL, une entité directement affiliée à Allergan Plc, un acteur majeur et globalement reconnu de l'industrie pharmaceutique, spécialisé dans le développement, la fabrication et la commercialisation de produits de marque dans des domaines thérapeutiques clés comme l'esthétique médicale, les neurosciences, l'ophtalmologie et la gastroentérologie, et bien que le pays d'émission principal soit désigné comme les États-Unis, l'émetteur direct est une société à responsabilité limitée basée au Luxembourg. Libellée en euros (EUR), cette obligation offre un taux d'intérêt nominal fixe de 2,625% et arrivera à maturité le 14 novembre 2028, avec des paiements d'intérêts effectués annuellement, contribuant à la régularité des flux de trésorerie pour les détenteurs; sur le marché secondaire, l'instrument se négocie actuellement à 95,17% de sa valeur nominale, ce qui indique une cotation à décote par rapport à son pair, suggérant soit une prime de rendement pour les nouveaux investisseurs par rapport au taux nominal, soit des anticipations de marché ou des conditions de liquidité qui justifient ce prix inférieur au pair.

FWP 1 d601733dfwp.htm FWP
Free Writing Prospectus
Filed pursuant to Rule 433
Registration Statement No. 333-223089-02
ALLERGAN FUNDING SCS
Pricing Term Sheet
Offering of
500,000,000 1.500% Notes due 2023
500,000,000 2.625% Notes due 2028
700,000,000 Floating Rate Notes due 2020
(the "Notes Offering")
This pricing term sheet relates only to the Notes Offering and should be read together with the preliminary prospectus supplement dated
November 8, 2018 relating to the Notes Offering (the "Notes Preliminary Prospectus Supplement"), the accompanying prospectus dated February 16,
2018 and the documents incorporated and deemed to be incorporated by reference therein. Certain capitalized terms used in this pricing term sheet that
are not defined herein have the respective meanings given to such terms in the Notes Preliminary Prospectus Supplement.
Issuer:
Allergan Funding SCS, a common limited partnership (société en commandite simple)
organized under the laws of the Grand Duchy of Luxembourg, having its registered office at
46A, avenue J.F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg, registered
with the Luxembourg Register of Commerce and Companies under number B187.310
Gross Proceeds to Issuer:
1,697,360,000
Guarantees:
Warner Chilcott Limited, Allergan Capital S.à r.l. and Allergan Finance, LLC will jointly and
severally, irrevocably and unconditionally guarantee the notes on an unsecured and
unsubordinated basis
Aggregate Principal Amount Offered:
500,000,000 aggregate principal amount of 1.500% notes due 2023 (the "2023 notes")
500,000,000 aggregate principal amount of 2.625% notes due 2028 (the "2028 notes")
700,000,000 aggregate principal amount of floating rate notes due 2020 (the "floating rate
notes")
(The 2023 notes and 2028 notes, together, the "fixed rate notes" and, the fixed rate notes and
the floating rate notes, together, the "Notes")
Listing:
The issuer intends to apply to list the notes on the New York Stock Exchange; there can be no
assurance that any such application will be successful or that any such listing will be granted
or maintained
Ranking:
General unsecured
Anticipated Ratings (Moody's / S&P):*
Baa3 (Stable) / BBB (Stable)
Coupon:
2023 notes:
1.500%
2028 notes:
2.625%
Floating rate notes: 3-month EURIBOR plus 0.350% per annum
Maturity:
2023 notes:
November 15, 2023
2028 notes:
November 15, 2028
Floating rate notes: November 15, 2020

Price to Public:
2023 notes:
99.628% of principal amount
2028 notes:
99.844% of principal amount
Floating rate notes: 100.000% of principal amount
Underwriting Discount:
2023 notes:
0.300% of principal amount
2028 notes:
0.425% of principal amount
Floating rate notes: 0.200% of principal amount
Yield to Maturity for Fixed Rate Notes:
2023 notes:
1.578%
2028 notes:
2.643%
Spread to Benchmark Bund for Fixed
2023 notes:
+172.2 basis points
Rate Notes:
2028 notes:
+219 basis points
Benchmark Bund for Fixed Rate Notes:
2023 notes:
OBL 0% due October 13, 2023
2028 notes:
DBR 0.25% due August 15, 2028
Benchmark Bund Yield for Fixed Rate
2023 notes:
-0.144%
Notes:
2028 notes:
0.453%
Spread to Mid-Swaps for Fixed Rate
2023 notes:
+120 basis points
Notes:
2028 notes:
+165 basis points
Mid-Swaps Yield for Fixed Rate Notes:
2023 notes:
0.378%
2028 notes:
0.993%
Interest Payment Date:
2023 notes:
Annually on November 15 of each year, beginning November 15, 2019
2028 notes:
Annually on November 15 of each year, beginning November 15, 2019
Floating rate notes: Quarterly on February 15, May 15, August 15 and November 15 of each
year, beginning February 15, 2019
Record Date:
2023 notes:
On November 1 of each year
2028 notes:
On November 1 of each year
Floating rate notes: 15th calendar day immediately preceding any interest payment date
(whether or not a business day)
Optional Redemption Fixed Rate Notes 2023 notes:
B+25 basis points prior to October 15, 2023
Make-Whole Call:
2028 notes:
B+35 basis points prior to August 15, 2028
Optional Redemption Fixed Rate Notes 2023 notes:
On or after October 15, 2023 (1 month prior to the maturity date for the
Par Call:
2023 notes)
2028 notes:
On or after August 15, 2028 (3 months prior to the maturity date for the
2028 notes)
Trade Date:
November 8, 2018
Settlement**:
November 15, 2018 (T+5)

CUSIP / ISIN:
2023 notes:
018489 AF1 / XS1909193150
2028 notes:
018489 AG9 / XS1909193317
Floating rate
018489 AE4 / XS1909193077
notes:
Denominations:
100,000 and increments of 1,000 in excess thereof
Joint Book-Running Managers:
Barclays Bank PLC
Goldman Sachs & Co. LLC
J.P. Morgan Securities plc
Morgan Stanley & Co. International plc
Additional Joint Book-Running
BNP Paribas
Managers:
Citigroup Global Markets Limited
HSBC Bank plc
Merrill Lynch International
Mizuho International plc
MUFG Securities EMEA plc
Co-Managers:
DNB Markets
SMBC Nikko Capital Markets Limited
The Toronto-Dominion Bank
Wells Fargo Securities International Limited
*
A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
**
We expect that delivery of the Notes will be made against payment therefor on or about the settlement date specified in this communication, which
will be the fifth business day following the date of pricing of the Notes (this settlement cycle being referred to as "T+5"). Under Rule 15c6-1 of
the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade
expressly agree otherwise. Accordingly, purchasers who wish to trade Notes on the date of pricing or the next two business days will be required,
by virtue of the fact that the Notes initially will settle in T+5, to specify an alternate settlement cycle at the time of any such trade to prevent a
failed settlement. Purchasers of the Notes who wish to make such trades should consult their own advisor.
Manufacturer target market (MiFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs
key information document has been prepared as the Notes are not available to retail investors in the EEA.
The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the "SEC") for the
offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and the related
prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering.
You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or
any dealer participating in the Notes Offering will arrange to send you the prospectus and related prospectus supplement if you request it by
calling (toll free): Barclays Bank PLC at 1-888-603-5847; Goldman Sachs & Co. LLC at (866) 471-2526; J.P. Morgan Securities plc collect at
+44 207 134 2468; or Morgan Stanley & Co. International plc at +44 20 7677 7799.